In up to a third of T-ALL patients carrying a JAK3 mutation, mutant JAK3 signaling is further enhanced by either the loss of wild type JAK3 or the acquisition of a secondary JAK3 mutation [99]. The gene discussed is JAK3; the disease is acute lymphoblastic leukemia.